Adeka (4401) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
27 Apr, 2026Executive summary
Net sales for the nine months ended December 31, 2025, were ¥296.7 billion, up 0.1% year-over-year, with operating profit at ¥29.3 billion, down 2.6%, and profit attributable to owners at ¥19.8 billion, up 3.4%.
Ordinary profit increased by ¥0.7 billion year-over-year to ¥30.3 billion.
Earnings per share rose to ¥196.9, an increase of ¥8.4 per share year-over-year.
Comprehensive income surged 51.8% year-over-year to ¥36,307 million.
Financial highlights
Gross profit for the period was ¥84,752 million, up from ¥84,034 million year-over-year.
Operating margin for the nine months was approximately 9.9%.
Net margin attributable to owners of parent was about 6.7%.
Overseas sales ratio stands at approximately 54%.
Annual dividend forecast maintained at ¥104 per share, with a payout ratio target of 40% or more.
Outlook and guidance
Full-year net sales forecast revised to ¥415 billion, up 1.9% year-over-year; operating and ordinary profit each forecast at ¥41.5 billion.
Profit attributable to owners of parent projected at ¥25.5 billion, up 1.9% year-over-year.
Earnings per share forecast at ¥257.7.
Recovery in polymer additives and semiconductor materials expected in Q4, with new product launches and market recovery anticipated.
Food products and life science segment outlooks remain unchanged; life science expects steady demand but higher fixed costs.
Latest events from Adeka
- Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 202610 Mar 2026 - Life Science strength drove profit growth, offsetting Chemicals and Food Products weakness.4401
Q2 202610 Mar 2026 - Profits and sales grew, led by Chemicals and Food Products, with raised outlook and Life Science loss.4401
Q1 202510 Mar 2026 - Strategic investments and innovation in semiconductor materials target rapid global growth.4401
Investor presentation10 Mar 2026 - 3Q FY2024 saw higher sales and profits, driven by Chemicals and global expansion.4401
Q3 202510 Mar 2026 - Strong 1H FY2024 results and Chemicals growth led to higher guidance and dividend forecasts.4401
Q2 202510 Mar 2026 - Record sales and profit growth driven by Chemicals, with continued expansion and higher dividends forecast.4401
Q4 202510 Mar 2026